PetIQ, Inc.

PETQ

US71639T1060

PetIQ, Inc. is a pet medication and wellness company, which provides veterinary products and services. The Company operates through two segments: Products and Services. Products segment manufactures and distributes pet medication and health and wellness products to major United States retail and e-commerce channels through more than 60,000 points of distribution. It is focused its offerings on value-branded products, and third-party branded products for dogs and cats, including pet Rx medications, OTC medications, and wellness products. Services segment provides a comprehensive suite of services at approximately 2,600 community clinic locations and wellness centers hosted at retailers across 39 states. The segmentâs services include diagnostic tests, vaccinations, prescription medications, microchipping, grooming and hygiene and wellness checks. The Rx pet medications products include flea and tick control, heartworm preventatives, arthritis, thyroid, and other specialty medications.

Employees

1,527

Sector

Pharmaceuticals

Calendar

07/11/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

30.68USD

Average target price

30.67USD

Spread / Average Target

-0.04%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 01:30:00 14/09/2024 am IST			5-day change	1st Jan Change
30.68 ^USD	+0.07%		+0.43%	+55.34%

08/08	Benchmark Downgrades PetIQ to Hold From Buy, Price Target is $30	MT
08/08	Truist Downgrades PetIQ to Hold From Buy, Lifts Price Target to $31 From $30 Amid Bansk Group Deal	MT

Benchmark Downgrades PetIQ to Hold From Buy, Price Target is $30	08/08	MT
Truist Downgrades PetIQ to Hold From Buy, Lifts Price Target to $31 From $30 Amid Bansk Group Deal	08/08	MT
Sector Update: Health Care Stocks Fall Late Afternoon	08/08	MT
Sector Update: Health Care	08/08	MT
PetIQ Agrees to $1.5 Billion Go-Private Deal With Bansk Group; Shares Soar	08/08	MT
Lake Street Downgrades PetIQ to Hold From Buy, Adjusts PT to $31 From $28	07/08	MT
William Blair Downgrades PetIQ to Market Perform From Outperform	07/08	MT
Top Midday Stories: Novo Nordisk Stock Slides After Q2 Miss, Lower Guidance; Disney EPS, Revenue Top Estimates; Apple's Union Workers Ratify Contract; Disney Likely to Pay More for Hulu	07/08	MT
PetIQ to Be Acquired by Bansk Group in $1.5 Billion Deal; Shares Jump	07/08	MT
PetIQ to Be Acquired by Bansk Group in $1.5 Billion Deal	07/08	MT
Earnings Flash (PETQ) PETIQ Reports Q2 Revenue $328.9M, vs. Street Est of $330.1M	07/08	MT
Earnings Flash (PETQ) PETIQ Reports Q2 EPS $0.70, vs. Street Est of $0.50	07/08	MT
Bansk Group to buy PetIQ for $1.5 billion	07/08	RE
PetIQ, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	07/08	CI
Bansk Group LLC entered into an Agreement and Plan of Merger to acquire PetIQ, Inc. for approximately $980 million.	07/08	CI
Tranche Update on PetIQ, Inc.'s Equity Buyback Plan announced on September 6, 2022.	09/05	CI
Transcript : PetIQ, Inc., Q1 2024 Earnings Call, May 08, 2024	09/05
Earnings Flash (PETQ) PETIQ Reports Q1 Revenue $308.4M, vs. Street Est of $300.4M	09/05	MT
Earnings Flash (PETQ) PETIQ Posts Q1 EPS $0.58	09/05	MT
PetIQ, Inc. Provides Earnings Guidance for the Second Quarter of 2024 and Revises Earnings Guidance for the Full Year 2024	09/05	CI
PetIQ, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
PetIQ, Inc. Announces Expansion of Minties Dental Treats Brand with Launch of New Dental Chew for Large-Sized Dogs	14/03	CI
Tranche Update on PetIQ, Inc.'s Equity Buyback Plan announced on September 6, 2022.	29/02	CI
Transcript : PetIQ, Inc., Q4 2023 Earnings Call, Feb 28, 2024	29/02
Earnings Flash (PETQ) PETIQ Reports Q4 Revenue $219.9M, vs. Street Est of $189M	29/02	MT

PetIQ, Inc.

Equities